|
Volume 15, Issue 3 (May 2013) 15, 356–357; 10.1038/aja.2012.166
The opportunity cost of androgen suppression in locally advanced prostate cancer
Phillip J Gray1,2, Jason A Efstathiou2 and William U Shipley2
1 Harvard Radiation Oncology Program, Boston, MA 02114, USA
2 Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Correspondence: Dr PJ Gray, (pjgray@partners.org)
Advance online publication 25 February 2013
| Abstract |
|
The use of androgen suppression therapy (AST) and radiotherapy for locally advanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk for side effects. Recently, Denham and colleagues have reported initial quality of life (QoL) results from the TROG 03.04 RADAR trial. The authors identify clinically meaningful decrements in patient-reported QoL for those treated with 18 months of AST vs. 6 months but only marginal differences at 36 months. Once survival data becomes available, these data will help to frame any benefits seen for longer courses of AST.
PDF |
PDF |
|
| |
| Browse: 4279 |
|
